ALX ONCOLOGY HOLDINGS INC
ALXO
NASDAQ
Upcoming IPOs
Expected Listing Date: - -
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-
-
-
-
-
2020-06-26
Public Filing
View Prospectus
Pending
Offering
Price Range: Pending
Shares to be Issued: Pending
Pending
Offering End Date
Offering Price: Pending
Post IPO Outstanding: Pending
Listed
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, ALX148, is a CD47 blocking therapeutic. ALX148 is a fusion protein that combines a CD47 binding domain with its inactivated fragment crystallizable (Fc) domain. The CD47 binding domain of ALX148 is an affinity enhanced extracellular domain of signal regulatory protein alpha (SIRPa), a protein that is the natural receptor to CD47 found on myeloid cells. Its programs are focused on targeting CD47 across various oncology indications.
More

Hot Stocks

Symbol
Price
%Change

Webull offers kinds of ALX ONCOLOGY HOLDINGS INC stock information, including NASDAQ:ALXO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALXO stock methods without spending real money on the virtual paper trading platform.